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Abstract 
Methamphetamine abuse is common among humans with immunodeficiency virus (HIV). 
The HIV-1 regulatory protein TAT induces dysfunction of mesolimbic dopaminergic systems 
which may result in impaired reward processes and contribute to methamphetamine abuse. 
These studies investigated the impact of TAT expression on methamphetamine-induced 
locomotor sensitization, underlying changes in dopamine function and adenosine receptors in 
mesolimbic brain areas and neuroinflammation (microgliosis). Transgenic mice with 
doxycycline-induced TAT protein expression in the brain were tested for locomotor activity 
in response to repeated methamphetamine injections and methamphetamine challenge after a 
7-day abstinence period. Dopamine function in the nucleus accumbens (Acb) was determined 
using high performance liquid chromatography. Expression of dopamine and/or adenosine A 
receptors (ADORA) in the Acb and caudate putamen (CPu) was assessed using RT-PCR and 
immunohistochemistry analyses.  Microarrays with pathway analyses assessed dopamine and 
adenosine signaling in the CPu. Activity-dependent neurotransmitter switching of a reserve 
pool of non-dopaminergic neurons to a dopaminergic phenotype in the ventral tegmental area 
(VTA) was determined by immunohistochemistry and quantified with stereology. TAT 
expression enhanced methamphetamine-induced sensitization. TAT expression alone 
decreased striatal dopamine (D1, D2, D4, D5) and ADORA1A receptor expression, while 
increasing ADORA2A receptors expression. Moreover, TAT expression combined with 
methamphetamine exposure was associated with increased adenosine A receptors 
(ADORA1A) expression and increased recruitment of dopamine neurons in the VTA. TAT 
expression and methamphetamine exposure induced microglia activation with the largest 
effect after combined exposure. Our findings suggest that dopamine-adenosine receptor 
interactions and reserve pool neuronal recruitment may represent potential targets to develop 
new treatments for methamphetamine abuse in individuals with HIV.  
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1. Introduction 
There is a high prevalence of methamphetamine abuse in HIV+ humans ranging 
between 40-60% (Rajasingham et al. 2012; Shoptaw et al. 2003). Neurotoxic effects of 
methamphetamine and HIV disease on the brain are well documented (Ferris et al. 2008; 
Purohit et al. 2011). However, studies on the brain adaptations that occur during early stages 
of methamphetamine use and HIV infection are uncommon.  
Methamphetamine reward is largely mediated by the dopaminergic system in 
corticolimbic brain areas including the medial prefrontal cortex (mPFC), nucleus accumbens 
(Acb), and ventral tegmental area (VTA) (Koob and Volkow 2010). HIV infection has been 
associated with impaired dopamine function in the basal ganglia (Kumar et al. 2011) and 
excessive glutamatergic function in frontal lobes (Nagarajan et al. 2012). Thus, dopamine and 
glutamate transmitter systems in corticolimbic circuits may be differentially affected in HIV+ 
subjects and alter sensitivity to methamphetamine.  
HIV viral products may contribute to neuropathology, reward deficits and drug 
dependence in treated patients (Merino et al. 2011). The viral TAT (trans-activator of 
transcription) protein is found in the central nervous system of HIV+ humans, even when 
serum CD4 levels are normalized with antiretroviral drugs (Mediouni et al. 2012). Transgenic 
mice that express the TAT protein in the brain, under the glial fibrillary acidic protein 
(GFAP) promoter and inducible by treatment with doxycycline, show neuropathology that is 
similar to that observed in HIV-infected humans (Kim et al. 2003), therefore providing a 
useful in vivo model to study the temporal impact of TAT protein on brain function. Moreover, 
TAT-induced dysfunction in corticolimbic dopaminergic neurotransmission (Ferris et al. 2009; 
Kesby et al. 2016b; Midde et al. 2012; Theodore et al. 2012; Zhu et al. 2009) may lead to 
alterations in reward function (Kesby et al. 2016b; Koob and Volkow 2010). We have 
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previously shown that the expression of HIV-associated proteins, such as gp120 and TAT, 
increase the sensitivity to methamphetamine reward (Kesby et al. 2016b; Kesby et al. 2014). 
The present studies investigated how HIV-1 TAT expression in the brain impacted 
dopamine and modified the reward function during methamphetamine-induced locomotor 
sensitization. Locomotor sensitization is the augmented motor-stimulant response after a 
period of abstinence that occurs with repeated, intermittent administration of 
psychostimulants. Such a phenomenon is thought to reflect aspects of the neuronal adaptations 
underlying drug dependence (Robinson and Berridge 2008), and mediated by both mesolimbic 
and mesocortical circuits (Steketee 2003).  
We also determined the activity-dependent induction of neurotransmitter re-
specification within a reserve pool of non-dopaminergic neurons to a dopaminergic 
phenotype in the ventral mesencephalon using quantification of the numbers of tyrosine 
hydroxylase (TH) - positive neurons (Dulcis and Spitzer 2008). Activity-dependent 
homeostatic plasticity in the brain involves changes in synaptic strength, number of synapses, 
neuronal excitability (Dulcis and Spitzer 2012; Nelson and Turrigiano 2008) and 
neurotransmitter expression (Dulcis et al. 2013). The presence of a reserve pool of neurons 
that can boost function of an endogenous circuit has been proposed as a novel mechanism of 
neuroplasticity (Dulcis and Spitzer 2012; Lewis et al. 2014; Velazquez-Ulloa et al. 2011). 
Indirect evidence for activity-dependent recruitment of a new population of neurons in 
amphetamine-sensitized rats (Nordquist et al. 2008) suggests this phenomenon may also be a 
feature in the development of psychostimulant abuse.   
Further, monoamine, glutamate and GABA function in the Acb was determined using 
high performance liquid chromatography (HPLC). The impact of TAT and methamphetamine 
on gene expression profile was determined in the brain tissue using microarrays followed by a 
  
5 
pathway analyses with a focus on dopamine signaling in the caudate putamen (CPu). Levels of 
dopamine receptors (DRD) and adenosine receptors (ADORA), that are co-expressed in the 
basal ganglia (Ferre et al. 1997) and involved methamphetamine reward (Chesworth et al. 
2016; Kavanagh et al. 2015; Pierce and Kalivas 1997; Shimazoe et al. 2000), were assessed and 
validated in the Acb and CPu using RT-PCR and immunohistochemistry (IHC) analyses. 
Finally, we also evaluated neuroinflammatory processes in the CPu by assessing expression of 
the ionized calcium binding adaptor molecule 1 (IBA-1), a marker for microglial activation 
(microgliosis). 
 
2. Materials and methods 
2.1. Animals 
A total of 82 male mice (3-5 months old), with 43 containing the GFAP promotor-
controlled Tet-binding protein (TAT-) and 39 containing both the GFAP promotor-controlled 
Tet-binding protein and the TRE promotor-TAT protein transgene (TAT+) were tested. 
Inducible TAT transgenic mouse colonies with a C57BL/6J background were obtained by 
generation of two separate transgenic lines Teton-GFAP mice and TRE-Tat86 mice, and then 
cross-breeding of these two transgenic mouse lines, as previously described (Kim et al. 
2003). The mice were housed in groups of 2-4 in a humidity- and temperature-controlled 
animal facility on a 12 h/12 h reverse light/dark cycle (lights off at 7:00 AM) with ad libitum 
access to food and water. Behavioral testing was conducted during the dark phase of the 
light/dark cycle from 8 AM to 7 PM with mice from all groups being tested concurrently at 
any given time throughout the testing period. All of the experiments were conducted in 
accordance with the guidelines of the American Association for the Accreditation of 
Laboratory Animal Care and National Research Council’s Guide for the Care and Use of 
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Laboratory Animals and approved by the University of California San Diego Institutional 
Animal Care and Use Committee. 
 
2.2. Locomotor activity testing 
Locomotor activity was assessed in four open field arenas (60 x 60 cm) equipped with 
infrared beams (Med Associates, St. Albans, VT, USA) to calculate total distance travelled. 
Mice were acclimatised to the testing room at least one hour prior to testing and were tested 
in the dark for a total of 30 min. 
 
2.3. Doxycycline regimen 
All mice were treated with a doxycycline regimen (doxycycline hyclate; Sigma) of 
100 mg/kg, intraperitoneally, once a day for 7 days. This regimen is based on the previously 
demonstrated efficacy of TAT induction at this dose of doxycycline (Carey et al. 2012; Paris 
et al. 2014a). Doxycycline-induced TAT expression was attenuated by day 7 and significantly 
decreased 14 days after the termination of doxycycline treatment (Paris et al. 2014a). Only 
mice containing both the GFAP promotor-controlled Tet-binding protein and the TRE 
promotor-TAT protein transgene (TAT+) generate TAT protein after doxycycline 
administration. Mice were administered doxycycline injections in the evening (17:00h), 
beginning the day before the methamphetamine acquisition phase.  
 
2.4. Methamphetamine sensitization 
The sensitization procedure consisted of an acquisition phase with seven consecutive 
days of locomotor testing directly after an intraperitoneal injection with either saline (0.9%) 
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or 2 mg/kg methamphetamine (methamphetamine hydrochloride; Sigma, St. Louis, MO, 
USA). The challenge phase occurred after a seven-day washout period. Mice were tested 
after either saline or 1 mg/kg methamphetamine. The methamphetamine doses were selected 
based on the literature (Jing et al. 2014). There were four testing groups: saline acquisition 
and saline challenge (SAL/SAL), methamphetamine acquisition and saline challenge 
(METH/SAL), saline acquisition and methamphetamine challenge (SAL/METH), 
methamphetamine acquisition and methamphetamine challenge (METH/METH).  
 
2.5. Neurochemical and molecular analyses 
Mice were euthanized via cervical dislocation 30 minutes after completing the 
locomotor challenge (1 h after injections of SAL/METH). Brain samples were rapidly 
dissected and samples frozen on dry ice and stored at -80
o
C until analysis. In a subgroup of 
these mice (n=5), from the SAL/METH and METH/METH groups, sample from one 
hemisphere were used for Bioinformatics (CPu) and PCR (Acb) studies. A separate subset of 
mice (n=4) from the SAL/METH and METH/METH groups were perfused 24 h after the 
locomotor challenge for dopamine cell counting in the SN and VTA. 
 
2.6. High performance liquid chromatography and analysis 
Catecholamines and amino acids from brain tissue were measured by high 
performance liquid chromatography with electrochemical detection for catecholamines and 
fluorescence detection for amino acids (Groves et al. 2013; Kesby et al. 2016a, c; Kesby et al. 
2009). Brain tissues were homogenized in 0.1 M perchloric acid with 50 ng/mL 
deoxyepinephrine (catecholamine internal standard) using probe sonication (Vibra-Cell, 
Sonics & Materials, CT, USA) and centrifuged at 13,000 rpm for 5 min. The supernatant was 
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filtered with a 4 mm 0.22 µM nylon syringe filter (MicroSolv Technology Corporation, NJ, 
USA). For catecholamines, 15 µL of sample was injected into the HPLC system, which 
consisted of an autosampler (Dionex UltiMate 3000, Thermo Scientific, CA, USA), an 
isocratic HPLC pump (Model 584, ESA Laboratories, MA, USA), a Sunfire C18 column, 
(4.6 mm × 100 mm, 3 um; Waters Corporation, MA, USA) and a Coulochem III (ESA 
Laboratories) electrochemical detector. The mobile phase consisted of a 12% acetonitrile/50 
mM citric acid and 25 mM potassium dihydrogen phosphate buffer containing 1 mM EDTA 
and 1.4 mM octane sulfonic acid adjusted to pH 4.3 with phosphoric acid. Flow rate was 0.5 
ml/min. An analytical cell (Model 5014B, ESA Laboratories) with the first and second 
electrodes maintained at –150 and +300 mV, respectively, was used for detection. Amino 
acids were analyzed using pre-column derivatization at 4◦C and fluorescence detection. The 
derivatisation protocol was conducted by the autosampler as follows: 10 µL of 1 nM/µL 
homoserine (amino acid internal standard) was mixed with 10 µL of sample; then 20 µL of 
borate buffer (0.4 M at pH 10) was added and mixed; then 5 µL of OPA reagent (100 mg o-
phthalaldehyde in 1 ml methanol with 9 ml borate buffer and 50 µl mercaptoethanol) was 
added and mixed; then after a 30 sec wait, 50 µL of mobile phase was added and mixed; 5 µl 
of the final solution was injected into the HPLC system. The system consisted of an isocratic 
pump and autosampler (Dionex UltiMate 3000, Thermo Scientific), and fluorescence detector 
(Model 2475, Waters Corporation) equipped with a Phenomenex Gemini C18 column (4.6 
mm × 150 mm, 3 um; Phenomenex, CA, USA). The mobile phase consisted of 0.05 M 
sodium acetate, tetrahydrofuran and acetonitrile (74:1:25, v/v) adjusted to pH 4.0 using 100% 
acetic acid. Flow rate was 1 ml/min and the fluorescence detector was set to an excitation 
wavelength of 337 nm and an emission wavelength of 454 nm. All data was stored and 
processed with Dionex Chromeleon software (version 7.2, Thermo Scientific). Data was 
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quantified by calculating peak-area ratios of each compound compared to the relevant 
internal standard. 
2.7. Gene expression array 
The integrity of total RNAs was examined in an Agilent Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA, USA). Total RNA concentration was measured using the 
Nanodrop spectrophotometer. The mouse Agilent microarray service was performed by 
Phalanx Biotech (San Diego, CA). A total of 4 μg Cy5-labeled RNA targets were hybridized 
to Gene Expression v2 4x44K Microarrays (Agilent Technologies, Santa Clara, CA), 
according to the manufacturer’s protocol. The data were analysed using the provided 
manufacturer’s protocol. Following the hybridization, fluorescent signals were scanned using 
an Axon 4000 (Molecular Devices, Sunnyvale, CA, USA). Five replicates per condition were 
used. Microarray signal intensity of each spot was analysed using the GenePix 4.1 software 
(Molecular Devices, Sunnyvale, CA, USA). Each signal value was normalized using the R 
program in the limma linear models package (Bioconductor 3.2, https://bioconductor.org).  
For the analysis of gene expression, raw data was loaded into ArrayStudio (Omicsoft 
Corporation, Cary, NC) and first filtered based on a built-in ANOVA, as well as a t-test, 
applied to fold changes between experimental and control conditions. Significant changes had 
a p value < 0.05. In addition, maximum least-squares (Max LS) mean ≥ 6, and a false 
discovery rate by the Benjamini-Hochberg correction (FDR_BH) <0.01 were applied. Using 
this method, many genes were found with raw p-values < 0.05, but if the FDR_BH did not 
reach < 0.01, they were discarded. In this particular analysis set, the genes were further 
filtered to express a robust above or below 3-fold significant, above background, gene 
expression change. The list of genes that were identified in the different groups following the 
described criteria, were loaded into Cytoscape 3.3 (http://cytoscape.org), using GeneMania 
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(Warde-Farley et al., 2010), to identify significantly changed interaction networks of genes, 
and relevant pathways, particularly assigned to neuroactive ligand-receptor interactions in the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) (www.genome.jp/kegg) and in Gene 
Ontology (GO) terms (http://geneontology.org/page/go-enrichment-analysis). 
 
2.8. RT-PCR 
RNA was reverse transcribed using SuperScript III Reverse Transcriptase (Invitrogen, 
Waltham, MA). Primers were purchased from Qiagen (Valencia, CA). PCRs were performed 
using RT² SYBR Green ROX FAST Mastermix (Qiagen), in a 7900HT Fast Real-Time PCR 
System with Fast 96-Well Block Module (Applied Biosystems, Foster City, CA) with a SDS 
Plate utility v2.2 software (Applied Biosystems). The results were normalized to the 
geometric mean of GAPDH and 18S housekeeping genes. 
2.9. Immunohistochemistry 
Following perfusion of the animal with ice-cold PBS, the brain tissue was harvested 
and fixed in 10% buffered formalin for 48 hrs, followed by 70% ethanol. Tissues were 
embedded in paraffin, cut into 5 µm sections, and mounted on glass slides. Rehydrated 
sections were blocked to endogenous peroxidase activity by treating slides with 3% hydrogen 
peroxide in absolute methanol. Following that, the slides were placed in a solution of 0.01M 
Citrate, pH 6.39, in a humidified heated chamber, for antigen exposure. Sections were 
blocked with 5g/l Casein (Sigma Aldrich) in PBS, containing 0.5g/l Thimerosal (Sigma 
Aldrich) and incubated with Iba-1 antibody (Wako Lab Chemicals, Richmond, VA), the anti-
mouse DRD1 antibody (NLS43, Novus Biologicals, Littleton, CO), or anti mouse DRD2 
(orb154598, Biorbyt, San Francisco, CA), each one diluted in Casein buffer. Biotinylated 
goat anti-rabbit IgG antibodies (Vector Labs, Burlingame, CA) were used at a 1/300 dilution. 
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Visualization was achieved using biotin/avidin-peroxidase (Vector Labs) and Nova Red 
(Vector Labs). Counterstaining was made with Gill’s hematoxylin. Images were captured 
using an Axiovert 200 inverted microscope (Carl Zeiss) with Axio Vision software (version 
4.8.1; Carl Zeiss). Image analysis was performed in Fiji/ImageJ (NIH, USA). For that, tiff 
image files were opened and manually thresholded to identify stained cells. A binary mask 
was obtained from the negative thresholded image and measurement values were calculated 
as percentage of the total area. This was performed in a minimum of 5 fields per section, and 
two sections per animal. The results are expressed as normalized intensity density. 
The DRD1 antibody was a rabbit polyclonal antibody against a Synthetic 15 amino 
acid peptide from the 3rd cytoplasmic domain of human DRD1, 94% conserved in mice. The 
DRD2 antibody was a rabbit polyclonal antibody against a synthetic 16 amino acid peptide 
from C-terminus cytoplasmic domain of human DRD2, conserved in both rats and mice. Both 
antibodies were positively validated in overexposed lysates by Western blot, and on cells that 
lack DRD1 and DRD2. Although validation was not performed in tissue-specific knockout 
mice, all the staining were performed in other tissues, including muscle, liver and spleen, that 
do not express or have small number of positive cells for these receptors. 
 
2.10.  Quantification of dopamine neuron recruitment 
Mice were deeply anesthetized, then intracardially perfused with 50 mL phosphate buffer 
solution (PBS) followed by 50 mL 4% ice-cold PFA (10 mL/min). Brains were harvested and 
post-fixed overnight in 4% PFA at 4°C, then cryo-protected in 30% sucrose for 48 hours. 
Brains were snap frozen on dry ice and 30 μm sections were collected with a standard Leica 
Microtome (SM 2010R). Horizontal brain sections were collected through the VTA and 
substantia nigra compacta (SNc) for each mouse and stored in PBS for immediate use or in 
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cryoprotectant for long-term storage at -20°C. VTA dopaminergic neurons were identified 
with standard 3,3′-diaminobenzidine (DAB) immunohistochemistry for tyrosine hydroxylase 
(TH). Section were washed 3 times for 10’ in PBS, then blocked in 5% horse normal 
serum/0.3% Triton in PBS for 1 hour before going in the primary antibody (mouse 
monoclonal anti-TH, 1:500, Millipore) solution overnight at 4°C. On the second day sections 
were washed for 3 times for 10’ in PBS then put in secondary antibody (biotinylated anti-
mouse, 1:100, Vector) solution for 1 hour at room temperature. Following 3 PBS washes, 
sections were incubated in ABC solution (Vector) for 1 hour, washed again 3 times and 
incubated in fresh DAB solution for 2-4 minutes. After 3 final washes in PBS sections were 
counterstained with GIEMSA, then mounted in gelatin on glass slides, and coverslipped with 
Cytoseal mounting media (Thermo Scientific). Stained tissue was imaged with a slide 
scanner (Leica Aperio Nanozoomer). Stereological quantification of TH+ neurons in the SNc 
and VTA subnuclei, PN and PBP, was performed blind with the Stereologer software 
(Stereology Resource Center, Inc).  
 
2.11.  Statistical analyses 
 All of the analyses were performed with IBM SPSS Statistics 20 (Armonk, NY, 
USA). Data were analyzed using analysis of variance (ANOVA), with TAT, 
Methamphetamine Exposure (during acquisition), Methamphetamine Challenge or Group as 
the between-subject factors. Repeated-measures ANOVAs were used when additional within-
subject factors were present (i.e., Bin or Day). TH+ cell counting data was analyzed non-
parametrically using the Jonckheere-Terpstra Test for ordered alternatives. The a priori 
hypothesis was that methamphetamine exposure alone would have a larger effect on TH+ 
neuron recruitment compared with TAT expression, but the combination of both would result 
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in the largest magnitude of change. When appropriate, post hoc comparisons were performed 
using Least Significant Difference (LSD) analyses. Results are expressed as mean ± SEM. 
Differences were considered statistically significant at p < 0.05. 
 
3. Results 
3.1. Methamphetamine-induced locomotor sensitization 
There were significant main effects of Day (F6,468=17.5, p<0.001) and 
Methamphetamine Exposure (F1,78=207.8, p<0.001), and a significant interaction of Day x 
Methamphetamine Exposure (F6,468=29.3, p<0.001) on locomotor activity. Methamphetamine 
increased the distance travelled compared with saline on all days of testing (p<0.001; Figure 
1). The distance travelled in response to repeated methamphetamine injections also increased 
across Days 1-3, whereas the response to saline remained consistent across all days of testing. 
No differences between TAT- and TAT+ mice were observed (Figure 1). 
 
<<Figure 1>> 
 
The response to saline and methamphetamine challenge on day 15 were analyzed 
separately as a repeated measure of 10 three-minute time bins with TAT and 
Methamphetamine Exposure as the between subject factors. For the saline challenge (Figure 
2A), there were significant main effects of Bin (F9,243=73.6, p<0.001) and Methamphetamine 
Exposure (F1,27=14.1, p<0.001) on distance travelled. Methamphetamine exposure during the 
acquisition phase increased the locomotor response to saline challenge across all time points 
compared with prior saline exposure.  
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For the methamphetamine challenge (Figure 2B), there were significant main effects 
of Bin (F9,423=8.1, p<0.001), Methamphetamine Exposure (F1,47=113.9, p<0.001), TAT 
(F1,47=7.5, p<0.01), and a significant interaction of Bin x Methamphetamine Exposure 
(F9,423=12.2, p<0.001). Methamphetamine exposure significantly increased the locomotor 
response to methamphetamine challenge in all mice. Overall, TAT+ mice showed higher 
locomotor activity than TAT- mice with the largest difference between genotypes after 
methamphetamine exposure (p<0.01).  
 
<<Figure 2>> 
 
3.2. Dopamine expression profiles and IBA-1 expression in the caudate putamen 
Using an Agilent mouse gene expression platform, we identified signature genes that 
characterize TAT expression, methamphetamine exposure during the acquisition phase, and 
their interaction in the CPu of mice challenged with methamphetamine. Interestingly, 
methamphetamine, compared with saline, caused a remarkable segregation of gene 
expression patterns in TAT- mice, affecting 8.6% of all the genes. TAT expression in saline-
exposed mice had a limited effect on gene expression, by affecting only 0.07% of all the 
genes. However, in methamphetamine-exposed mice, TAT expression affected over 10% of 
the genes analysed. This was confirmed by predictions using General Linear model.  
A substantial number of gene signatures overlapped with anti-correlated interactions, 
when methamphetamine exposure was compared to saline exposure in TAT- mice, and when 
methamphetamine exposure in TAT+ mice was compared to methamphetamine exposure in 
TAT- mice. We identified patterns that distinguished the groups, by focusing on genes in the 
dopamine system. We detected a significant effect of TAT on the expression of DRDs, and  
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molecules associated with the dopamine system pathway. Figure 3 shows the graphical 
representation of these comparisons, as determined by a systems analysis using GeneMania 
Mus musculus network, excluding predicted interactions, in the Cytoscape platform. The 
examination of the effects of TAT expression (TAT+ vs. TAT- after exposure to saline; 
Figure 3A) showed a significant downregulation of DRD4, Intersectin 1 (Itsn1) and 
Peptidylglycine Alpha-Amidating Monooxygenase (Pam), while genes such as the Gamma-
Aminobutyric Acid Type A Receptor Theta Subunit (Gabrq) were upregulated. Similarly, 
methamphetamine exposure compared to saline exposure in TAT- mice; Figure 3B) caused a 
decrease of the expression of DRD4 and Pam, and also decreased DRD1a, DRD2, DRD3, 
regulatory molecules ADORA1 and ADORA2B, as well as epsilon (ε)-sarcoglycan (Sgce), 
Regulator Of G-Protein Signalling 20 (Rgs20), Ubiquitin C-Terminal Hydrolase L1 (Uchl1), 
NADH-ubiquinone oxidoreductase complex (complex I) of the mitochondrial respiratory 
(Ndufv2), and Monooxygenase, DBH-Like 2 (Moxd2). The effects of methamphetamine 
exposure in the context of TAT expression (methamphetamine vs saline exposure in TAT+ 
mice; Figure 3C) showed a modest effect in the dopamine system, although a trend for 
downregulation was maintained. In this case, though, methamphetamine exposure in TAT+ 
mice caused a significant increase in Pam levels and a significant decrease in Tata-box 
binding peptide (Tbp) levels. The effects of TAT expression in the context of 
methamphetamine exposure (TAT+ vs. TAT- mice exposed to methamphetamine; Figure 
3D) increased DRD4, ADORA1 and ADORA2b, as well as Ndufv2, Cdnf and Uchl1.  
 
<<Figure 3>> 
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 In addition, we performed IHC analyses to estimate changes of intensity and 
distribution of the molecules of DRD1 and DRD2 at the protein level in the CPu (Figure 4). 
For DRD1, there was a significant main effect of TAT (F3,16=107.1, p<0.0001). TAT+ mice 
had a significantly lower intensity density of DRD1 protein expression than TAT- mice 
independent of methamphetamine exposure. For DRD2, there were significant main effects 
of TAT (F3,16=56.5, p<0.0001), Methamphetamine exposure (F3,16=13.2, p<0.01) and their 
interaction (F3,16=9.9, p<0.01). TAT+ SAL group had a significantly lower intensity density 
of DRD2 protein expression than TAT- SAL group (p<0.01); while TAT+ METH+ group 
had a significantly lower intensity density of DRD2 protein expression compared to all other 
groups (p<0.001). 
 We also examined whether TAT and/or methamphetamine had an effect on IBA-1, a 
marker for microglia activation (Figure 4). For IBA-1 intensity density, there were 
significant main effects of TAT (F3,16=7.7, p<0.05), Methamphetamine exposure (F3,16=28.1, 
p<0.001) but no interaction. A step-wise increase in the IBA-1 intensity density between the 
groups was observed, with the TAT- SAL group showing the lowest IBA-1 intensity density 
followed by the TAT+ SAL group and the TAT- METH group, with the greatest IBA-1 
intensity density in the TAT+ METH group (linear trend analyses: slope 0.000665, R
2
=0.75, 
p<0.0001). 
 
<<Figure 4>> 
 
3.3. Nucleus accumbens neurochemistry, dopamine and adenosine receptors expression 
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Levels of norepinephrine, dopamine, serotonin, glutamate, GABA, and associated 
metabolites, in the Acb were not significantly different between TAT- and TAT+ mice, 
regardless of methamphetamine exposure or challenge (Table 1 and Table 2).  
In mice challenged with methamphetamine, there were significant main effects of 
TAT for the levels of all DRDs: DRD1 (F1,16=9.3, p<0.01), DRD2 (F1,16=35.6, p<0.001), 
DRD4 (F1,16=9.3, p<0.01) and DRD5 (F1,16=7.9, p<0.05). In addition, TAT+ mice had 
decreased levels of all the DRDs compared with TAT- mice, regardless of methamphetamine 
exposure (Figure 5A). There were no differences between groups in the intensity density for 
DRD1 and DRD2 in the Acb (data not shown). 
For the ADORAs, there were significant main effects of TAT for ADORA2A 
(F1,16=16.6, p<0.001) and of Methamphetamine Exposure for ADORA1 (F1,16=8.6, p<0.01), 
ADORA2A (F1,16=5.8, p<0.05) and ADORA2B (F1,16=7.4, p<0.05).  TAT+ mice had 
significantly increased ADORA2A receptor levels compared with TAT- mice, regardless of 
methamphetamine exposure (Figure 5B). Methamphetamine exposure decreased the levels of 
all ADORA compared with saline exposure. There was also a significant interaction of 
Methamphetamine Exposure x TAT for the ADORA1 receptor (F1,16=12.8, p<0.01). 
Methamphetamine exposure significantly lowered levels of the ADORA1 receptor in TAT- 
mice compared with saline treatment (p<0.001) but did not in TAT+ mice (Figure 5B). 
 
<<Figure 5; Table 1; Table 2>> 
 
3.4. Quantification of Dopaminergic neurons 
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We examined whether TAT and/or methamphetamine had an effect on the recruiting 
of a newly expressing dopaminergic neuronal pool. For that, TH+ neurons were detected in 
dopaminergic nuclei of the ventral tegmental area (VTA) and substantia nigra pars compacta 
(SNc) by immunohistochemistry using the colorimetric DAB amplification system (Figure 
6A). The number of TH+ neurons (Figure 6D) were significantly different between groups in 
the parabrachial pigmented region (PBP, Figure 6B-C) of the VTA (TJT=2.9, p<0.01). 
Methamphetamine exposure increased the number of TH+ neurons in both TAT- (p<0.05) 
and TAT+ (p<0.05) mice compared with TAT- SAL/METH mice. A step-wise increase in the 
number of TH+ cells between the groups was observed, with the TAT- SAL/METH group 
showing the lowest number followed by the TAT+ SAL/METH group and the TAT- 
METH/METH group, with the greatest level number of TH+ cells in the TAT+ 
METH/METH group.  
 
<<Figure 6>> 
 
4.  Discussion 
 The present studies demonstrate that brain-specific TAT expression during 
methamphetamine exposure augments methamphetamine-induced locomotor sensitization. 
TAT expression, regardless of methamphetamine sensitization, decreases striatal DRD and 
ADORA expression. The combination of TAT expression and methamphetamine 
sensitization was associated with increased expression of ADORAs (specifically, 
ADORA1A) and induction of neurotransmitter plasticity (Dulcis and Spitzer 2008, 2012; 
Dulcis et al. 2013) measured as an increased number of dopamine neurons in the parabrachial 
pigmented region of the VTA. These results demonstrate that combined TAT expression and 
  
19 
methamphetamine exposure alter dopamine signaling and enhance the recruitment of reserve 
pool neurons of non-dopaminergic neurons to a dopamine phenotype. Previous evidence of 
increased sensitivity to methamphetamine reward (Kesby et al. 2016b), which occurs in 
addition to methamphetamine-induced increase in activity, suggests that HIV-positive 
subjects may be more susceptible to the effects of methamphetamine compared to HIV-
negative subjects. Finally, TAT expression and methamphetamine exposure significantly 
increased microglia activation indicative of increased inflammatory processes with the largest 
effect after combined exposure.  
 TAT expression has been shown to increase the rewarding effects of 
methamphetamine (Kesby et al. 2016b), ethanol (McLaughlin et al. 2015) and cocaine (Paris 
et al. 2014c). However, the effects of TAT exposure on psychostimulant-induced locomotor 
sensitization are mixed. For example, TAT-expressing mice and rats with intra-Acb TAT 
injections show an increased locomotor response to acute cocaine (Harrod et al. 2008; Paris 
et al. 2014c). However, intra-Acb injections of TAT before or after acquisition of cocaine 
sensitization have been shown to decrease sensitized locomotor responses (Ferris et al. 2010; 
Harrod et al. 2008). Similarly, intra-VTA TAT injections attenuate nicotine sensitization in 
rats (Zhu et al. 2015). However, it is not known whether acute local injections of the TAT 
protein are comparable to the prolonged TAT expression of TAT-expressing mouse model 
utilized in our study (Paris et al. 2014b). Importantly, locomotor response to repeated 
methamphetamine injections was similar in TAT+ and TAT- mice indicating similar 
sensitivity to methamphetamine during the acquisition phase. Thus, our data suggests that the 
period of abstinence prior to challenge is critical to reveal increased sensitivity to 
methamphetamine-induced sensitization in TAT+ mice.  
 In a rat model of amphetamine sensitization, increases in c-Fos reactive cells were 
observed in a direct target of the VTA, the Acb (Nordquist et al. 2008), suggesting a 
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functional link between increased activity of dopamine neurons, which are recruited in 
response to amphetamine after sensitization, and the Acb. Our results are the first example, to 
the best of our knowledge, of neurotransmitter plasticity associated with methamphetamine 
sensitization eliciting an increase in the number of newly expressing dopamine neurons. 
Because a greater number of dopamine neurons was observed following TAT expression and 
methamphetamine sensitization, a potential neuroadaptive response to chronic 
psychostimulant exposure might occur in HIV infection. The recruitment of dopaminergic 
neurons was specific to the parabrachial pigmented region of the VTA while SNc was 
unaltered, consistent with the existence of dopamine projections from this region to the Acb 
(Lammel et al. 2014) and a key role in the induced locomotion (Heusner et al. 2003). In our 
previous studies (Dulcis and Spitzer 2008; Dulcis et al. 2013), we found that neurotransmitter 
plasticity is regulated at the transcriptional level and that newly-expressing dopaminergic 
neurons start expressing de novo TH transcripts following induction. Understanding the 
mechanism of gene regulation behind methamphetamine-induced dopamine plasticity in 
TAT+ mice is an important question that we would like to address in the near future. Our 
behavioral and functional findings associated with changes in the number of dopaminergic 
neurons in the VTA could result from either transcriptional or translational regulation that 
ultimately would increase dopamine expression and release in the Acb. However, although 
we found evidence of a greater population of dopamine neurons in the VTA, we did not 
observe alterations in dopamine levels or turnover within the Acb. This result is not 
surprising because the effects of TAT expression on dopamine levels are time-dependent. 
That is, in our previous work, TAT expression does alter dopamine and serotonin levels three 
days after the final doxycycline treatment (Kesby et al. 2016b), but this effect dissipated by 
later time points with monoamine levels similar in TAT+ and TAT- mice (Kesby et al. 
2016b; Kesby et al. 2016c). Therefore, the availability of more dopamine neurons alongside 
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parallel changes in receptor expression, would appear sufficient to explain the augmented 
sensitization behavior observed in TAT+ mice.  
A complex relationship between TAT expression and methamphetamine exposure 
was revealed by the differential impact of these factors on receptor expression. The 
expression of molecules associated with the dopaminergic system, such as the DRDs and the 
ADORAs, was particularly affected both by TAT and methamphetamine, combined or alone, 
In both the Acb and CPu, induction of TAT expression tended to downregulate DRD mRNA 
and protein levels when compared with similarly treated TAT- mice, suggesting a general 
effect on dopamine neurons. However, some discrepancies between gene expression and 
protein expression for DRDs were also observed. For example, after methamphetamine 
exposure we observed increased DRD mRNA expression in the CPu of TAT+ compared with 
TAT- mice, whereas, DRD2 protein expression was decreased. Multiple factors could 
contribute to differential mRNA and protein expression outcomes, such as the half-life of 
proteins and mRNA degradation rates, the lower rate of mRNA transcription compared to 
protein translation in mammalian cells (Vogel and Marcotte 2012). An additional 
contributing factor to consider is the acute effects of methamphetamine challenge (likely 
observed in mRNA expression) versus chronic effects of methamphetamine exposure during 
acquisition and TAT induction phases (likely observed in protein levels). Nevertheless, these 
data suggest that dopamine systems are profoundly affected by both methamphetamine and 
TAT exposure.  
Both the Acb and CPu are heavily involved in the transition to drug dependence 
(Everitt and Robbins 2013). Adaptations in the CPu has been associated with 
methamphetamine sensitization (Li et al. 2016a; Li et al. 2016b; Yan et al. 2014). However, 
the subdivisions of the striatum have important functional differences that need to be 
considered (Boekhoudt et al. 2016). Indeed, we have previously shown that the effects of 
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TAT expression on dopamine levels in the CPu and Acb are opposing in nature (Kesby et al. 
2016b). Further, our results suggest a differential recruitment of TH+ cells in parabrachial 
pigmented region of the VTA, but not the SN, which may instead support differential effects 
on striatonigral and mesolimbic dopamine circuitry.  
Similar to DRDs, increased ADORA receptor expression both in the CPu and Acb 
was observed in TAT+ mice exposed to methamphetamine compared to TAT-mice. In the 
Acb, ADORA1 receptor levels were significantly increased in methamphetamine sensitized 
TAT+ mice compared with methamphetamine sensitized TAT- mice. In addition, regardless 
of methamphetamine exposure, TAT expression also led to increased levels of ADORA2A. A 
complex balance between ADORA1 and ADORA2A receptors is required for functional 
dopaminergic signaling. For example, ADORA1 receptors inhibit whereas, ADORA2A 
receptors stimulate dopamine and glutamate release in the Acb (Quarta et al. 2004). In 
addition, stimulation of ADORA1 receptors negatively affects DRD1 binding, while 
stimulation of ADORA2A receptors decreases the affinity for DRD2 (Franco et al. 2000). 
The differential feedback pathways involving striatal DRD1 and DRD2-bearing neurons in 
locomotion are also complex (Calabresi et al. 2014). Thus, the control of psychostimulant-
induced locomotion involves the contribution of multiple factors including dopamine neuron 
function and a balance between DRD1 and DRD2 pathways. The combination of TAT 
expression and methamphetamine sensitization may likely disrupt such balance.  
The systems analysis was instrumental in identifying other potential genes contributing to 
the enhanced sensitivity to methamphetamine in TAT+ mice.  For example, the 
Peptidylglycine Alpha-Amidating Monooxygenase (Pam) gene, which was independently 
downregulated by methamphetamine exposure or by TAT expression, was upregulated by the 
combined methamphetamine exposure in the context of TAT expression. Pam is an essential 
cuproenzyme and regulator of copper homeostasis in neuroendocrine cells. More recently, 
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Pam has been identified as a possible cellular oxygen sensor (Simpson et al. 2015) suggesting 
our observations may be in response to oxidative stress or hypoxia induced by TAT, 
methamphetamine or a combination of the two. Both methamphetamine exposure and TAT 
expression are associated with oxidative stress (Krasnova and Cadet 2009; Mediouni et al. 
2015). Multiple other genes, including Ndufv2 (NADH dehydrogenase [ubiquinone] 
flavoprotein 2), Cdnf (Conserved dopamine neurotrophic factor) and Uchl1 (ubiquitin C-
terminal hydrolase-L1), were also upregulated in sensitized TAT+ mice compared with 
sensitized TAT- mice. These genes are strongly associated with dopaminergic systems and 
oxidative stress. For example, Ndufv2 is a mitochondrial protein associated with oxidative 
stress, aging and a range of neuropsychiatric disorders (Tatarkova et al. 2016). Cdnf is an 
neurotrophic factor that promotes the survival of midbrain dopaminergic neurons (Lindahl et 
al. 2016). Therefore, upregulation of Cdnf in methamphetamine-sensitized TAT+ mice 
compared with methamphetamine-sensitized TAT- mice may be in response to increased 
levels of oxidative stress, and it may be compatible with our observation of increases in the 
reserve pool neuron recruitment to a dopaminergic phenotype. Uchl1 is important in the 
removal of oxidized/damaged proteins and decreases are associated with neurodegenerative 
disorders (Tramutola et al. 2016). Thus, upregulation of this gene in sensitized TAT+ mice 
compared with TAT- mice could be a result of increased levels of oxidized/damaged proteins 
or alternatively, of oxidative damage to Uchl1 itself, which can lead to functional impairment 
(Tramutola et al. 2016). Indeed, higher levels of Uchl1 after traumatic brain injury are 
associated with worse outcomes (Takala et al. 2016). The genetic changes observed in the 
present study are indicative of neuronal damage. Cerebral microgliosis, suggesting neuronal 
damage, has been reported in humans with HIV and life-time methamphetamine abuse 
(Soontornniyomkij et al. 2016). In our model, we have identified evidence of glial activation 
as demonstrated by increased IBA-1 expression in the CPu, particularly in the 
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methamphetamine-exposed groups, which was further enhanced by TAT expression. The 
changes in these genes caused by TAT protein and methamphetamine exposure further 
highlight the importance of TAT expression in the brain, in the context of drug sensitization, 
on a network of genes regulating the dopaminergic system and reward function.   
5. Conclusions 
 We present experimental evidence that the combination of HIV-related protein TAT 
and methamphetamine exposure affects molecular pathways that may lead to altered reward 
and cognitive function in HIV+ individuals with methamphetamine abuse. Our work 
demonstrates that the HIV-associated TAT protein augments the neurobiological adaptations 
underpinning sensitization to methamphetamine in mice. These adaptations include increases 
in the number of VTA dopamine neurons, altered expression of DRDs and ADORAs, and 
dysregulation of a network of genes associated with both the dopamine system and oxidative 
stress. The transient expression of the TAT protein also suggests that these adaptations persist 
in the absence of the TAT protein. Further studies on the role of ADORAs and on the 
contribution of newly expressing dopamine neurons, in the context of HIV and 
methamphetamine, may shed light on potential therapeutic targets for comorbid 
methamphetamine abuse in HIV+ individuals.  
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Figure Legends 
Figure 1. Effects of TAT protein expression on locomotor activity during repeated 
methamphetamine administration.  
Mice were treated daily with saline (SAL) or 2 mg/kg methamphetamine (METH; striped 
bars) and the total distance travelled (cm) over 30 min was assessed.  Methamphetamine 
exposure significantly increased locomotor activity compared with saline at all days of 
testing. Methamphetamine-induced increases in locomotor activity were larger on Day 2 than 
Day 1, and on Day 3 compared to Day 2 (P< 0.001). No differences between TAT- and 
TAT+ mice were observed on the distance travelled after saline or methamphetamine. Data 
are expressed as Mean ± SEM (n=19-23). *** p < 0.001. 
#
 p < 0.001 compared to saline 
treatment on the corresponding day of testing.  
 
Figure 2. Effects of TAT protein expression and methamphetamine exposure on the 
sensitized locomotor response. 
Locomotor responses to challenge with saline (A) or methamphetamine (B) in saline (SAL; 
circles) or methamphetamine (METH; squares)-exposed mice. Exposure to 
methamphetamine significantly increased the distance travelled in mice after both saline (A) 
and methamphetamine challenge (B). In response to the METH challenge, METH-exposed 
TAT+ mice travelled significantly more than METH-exposed TAT- mice (B), suggesting 
enhanced methamphetamine sensitization. Data are expressed as Mean ± SEM (SAL 
challenge: n=7-9, METH challenge n=11-14). * p < 0.05, ** p < 0.01, *** p < 0.001 between 
TAT- and TAT+ mice exposed to methamphetamine during the acquisition phase. 
# # #
 p < 
0.001 between mice exposed to saline or methamphetamine during the acquisition phase.  
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Figure 3. Gene networks associated with the dopaminergic system. 
Gene changes induced by TAT expression in the brain after exposure to saline (SAL) or 
methamphetamine (METH) (n=5) in mice challenged with METH. A) Differences between 
TAT- and TAT+ mice exposed to SAL and challenged with METH. B) Differences between 
METH and SAL exposure in TAT- mice challenged with METH. C) Differences between 
METH and SAL exposure in TAT+ mice challenged with METH. D) Differences between 
TAT- and TAT+ mice exposed to METH and challenged with METH. Orange line 
connectors represent genes with shared protein domains or pathway interactions, and gray 
line connectors represent genes that are co-expressed or co-localized. Green colored shapes 
represent down regulated genes and Red colored shapes represents upregulated genes. Gray 
colored circles represent genes in the identified network that were not represented in the 
Agilent gene array platform. Squares represent p < 0.05 between two assigned groups. 
 
Figure 4. Caudate putamen dopamine receptors expression and IBA-1 expression. 
Immunohistochemistry on paraffin embedded sections was utilized examine the protein 
distribution and levels of dopamine receptor D1 (A, B, C, D), dopamine receptor D2 (E, F, G, 
H), as well as of IBA-1 (I, J, K, L) in SAL TAT- (A, E, I), SAL TAT+ (B, F, J), METH 
TAT- (C, G, K), and METH TAT+ (D, H, L) mice. Representative positive cells in the 40x 
magnification images were labeled with a black arrow. (M) Normalized intensity density was 
calculated in ImageJ.  Data are expressed as Mean ± SEM (n=5). * p < 0.05, ** p < 0.01, *** 
p < 0.001    
 
Figure 5. Nucleus accumbens dopamine and adenosine receptor expression. 
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Effects of TAT protein expression on nucleus accumbens dopamine receptor (DRD; A) and 
adenosine receptor (ADORA; B) expression in response to methamphetamine challenge after 
exposure to saline (SAL) or methamphetamine (METH). TAT expression, regardless of 
methamphetamine exposure decreased the expression of all DRDs (A). Methamphetamine 
exposure, regardless of TAT expression, decreased the expression of the ADORAs (B). TAT 
expression increased levels of ADORA2A and prevented the reduction of ADORA1 by 
methamphetamine exposure. Data are expressed as Mean ± SEM (n=5). * p < 0.05, ** p < 
0.01, *** p < 0.001    
 
Figure 6. Recruitment of reserve pool neurons to a dopaminergic phenotype. 
A. Horizontal midbrain section immunostained for tyrosine hydroxylase (TH), showing the 
substantia nigra pars compacta (SNc) and ventral tegmental subregions (perinigral, PN; 
parabrachial pigmented, PBP). B-C. Representative images of the VTA sectioned through the 
PBP of a TAT- SAL mouse (B) and a TAT+ METH mouse (C); black arrows indicate TH+ 
neurons. D. Graph showing the effects of TAT protein expression (TAT- and TAT+) on 
(TH)-positive cell number (mean cell count per hemi section) after prior exposure to saline or 
to methamphetamine. Both TAT expression and prior methamphetamine exposure tended to 
increase TH-positive cell numbers in the PBP with combined TAT expression and prior 
methamphetamine exposure producing the greatest number of TH-positive cells. Data are 
expressed as Mean ± SEM (n=4). Scale bars: a, 100 µm; b-c, 10 µm). * p < 0.05, ** p < 0.01. 
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Table 1. Neurotransmitter levels in the nucleus accumbens after saline challenge. 
 TAT-/SAL TAT+/SAL TAT-/METH TAT+/METH 
 Mean SEM Mean SEM Mean SEM Mean SEM 
Adrenergic system         
NE 257.60 62.33 199.83 48.32 195.89 25.87 184.50 36.11 
Dopamine system         
DA 12428.6 433.0 12850.1 235.3 12519.4 637.5 12925.5 497.6 
DOPAC 1153.38 42.17 1131.50 23.86 1206.70 35.34 1173.09 45.79 
3-MT 445.79 34.23 397.04 25.70 413.85 26.63 399.51 25.01 
HVA 1131.4 47.88 1115.8 63.24 1125.8 50.71 1197.4 43.43 
DOPAC/DA 0.0931 0.0032 0.0882 0.0020 0.0977 0.0037 0.0912 0.0032 
HVA/DA 0.0910 0.0022 0.0866 0.0035 0.0904 0.0023 0.0932 0.0036 
3-MT/DA 0.0358 0.0021 0.0310 0.0022 0.0341 0.0032 0.0312 0.0022 
DOPAC/HVA 1.0289 .0505 1.0276 0.0422 1.0794 0.0254 0.9906 0.0579 
Serotonin system         
5-HT 744.94 46.22 686.89 45.14 703.56 41.51 708.25 28.16 
5-HIAA 431.29 26.36 412.39 31.06 422.94 27.96 435.21 34.57 
5-HIAA/5-HT 0.5839 0.0339 0.6081 0.0494 0.6038 0.0256 0.6153 0.0415 
Amino acids         
GLU 1563.10 53.26 1598.64 89.98 1621.36 34.81 1619.59 57.45 
GABA 284.24 26.78 242.07 21.61 245.71 7.64 242.94 17.72 
Glutamine 1286.16 66.95 1394.61 183.40 1283.28 111.88 1310.21 107.90 
GLU/GABA 5.74 0.47 6.87 0.65 6.65 0.24 6.92 0.54 
Gln/GLU 0.8253 0.0398 0.8724 0.1015 0.7914 0.0654 0.8245 0.0869 
SAL, saline exposure; METH, methamphetamine exposure; SEM, standard error of the mean; 
NE, norepinephrine; DA, dopamine; DOPAC, dihydroxyphenylacetic acid; 3-MT, 3-
methoxytyramine; HVA, homovanillic acid; 5-HT, serotonin; 5-HIAA, 5-hydroxy-
indoleacetic acid; GLU, glutamate; GABA, γ-aminobutyric acid; Gln, glutamine. (n=7-9).  
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Table 2. Neurotransmitter levels in the nucleus accumbens after methamphetamine 
challenge. 
 TAT-/SAL TAT+/SAL TAT-/METH TAT+/METH 
 Mean SEM Mean SEM Mean SEM Mean SEM 
Adrenergic system         
NE 200.62 25.88 256.00 61.29 293.23 46.19 378.88 106.91 
Dopamine system         
DA 11698.0 1058.86 12733.2 909.38 13888.6 744.36 12503.3 846.17 
DOPAC 731.56 77.21 784.01 64.40 808.80 41.55 764.25 52.11 
3-MT 477.18 31.26 539.01 32.63 534.03 19.69 500.37 36.89 
HVA 769.66 43.29 835.12 34.43 888.12 57.26 896.02 45.13 
DOPAC/DA 0.0627 0.0026 0.0617 0.0026 0.0585 0.0019 0.0614 0.0024 
HVA/DA 0.0682 0.0036 0.0669 0.0027 0.0642 0.0033 0.0727 0.0041 
3-MT/DA 0.0422 0.0024 0.0427 0.0014 0.0393 0.0022 0.0401 0.0015 
DOPAC/HVA 0.9393 0.0636 0.9352 0.0545 0.9242 0.0393 0.8570 0.0496 
Serotonin system         
5-HT 735.50 45.03 738.48 38.02 800.66 36.27 833.68 78.32 
5-HIAA 320.03 25.83 331.25 22.42 368.01 29.37 361.21 36.86 
5-HIAA/5-HT 0.4336 0.0252 0.4530 0.0315 0.4611 0.0326 0.4456 0.0484 
Amino acids         
GLU 1468.38 48.65 1362.54 66.52 1440.24 51.14 1359.81 79.59 
GABA 261.89 20.10 284.40 20.39 301.53 21.95 340.87 44.71 
Glutamine 1175.48 46.65 1172.80 74.56 1337.87 105.94 1385.66 164.16 
GLU/GABA 5.93 0.54 5.07 0.52 4.97 0.35 4.59 0.81 
Gln/GLU 0.8117 0.0522 0.8708 0.0601 0.9276 0.0622 1.0332 0.1244 
SAL, saline exposure; METH, methamphetamine exposure; SEM, standard error of the mean; 
NE, norepinephrine; DA, dopamine; DOPAC, dihydroxyphenylacetic acid; 3-MT, 3-
methoxytyramine; HVA, homovanillic acid; 5-HT, serotonin; 5-HIAA, 5-hydroxy-
indoleacetic acid; GLU, glutamate; GABA, γ-aminobutyric acid; Gln, glutamine. (n=7-10). 
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Highlights 
TAT expression in the brain enhances sensitivity to methamphetamine. 
TAT expression decreased striatal dopamine receptors expression. 
TAT expression and methamphetamine increased recruitment of midbrain dopamine neurons. 
TAT expression and methamphetamine differentially modulated adenosine receptors 
expression. 
TAT-induced neuroadaptations may contribute to comorbid methamphetamine abuse and 
HIV.  
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